40:I[185,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SendEmailButton"] 42:I[63625,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"AddToLibraryButton"] 43:I[29721,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ShareButton"] 44:I[58016,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ProcessEpisodeButton"] 45:I[45269,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SignupCTA"] 3a:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2025-05-09T13:00:00.000Z","children":"May 9, 2025"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:38:19"}],false]}] 41:T54f,

This week on The Rob & Jai Show, an edition of the OIS Podcast, Perry Sternberg, CEO of Sydnexis, discusses the company's efforts to bring its innovative SYD-101 product to market, which aims to slow the progression of pediatric myopia.

Challenges in Market Access: Sternberg emphasizes the challenges of market access and reimbursement, explaining that it's not just about the product’s price but also the value proposition it offers.
Launch Plans for 2026: The company is planning for a 2026 launch, following FDA approval, with a strong focus on ensuring a positive experience for both physicians and patients.
Global Significance of SYD-101: He highlights the global significance of SYD-101, particularly in regions with high rates of myopia like Asia, where the need for effective solutions is critical.
Personal Mission: Reflecting on his personal mission, Sternberg expresses his desire to make a meaningful impact on children’s vision and future health.
The hosts applaud his leadership and the potential of this product to make a lasting difference in the lives of patients affected by progressive myopia.

To learn more about SYD-101 and the exciting developments in pediatric myopia treatment, be sure to listen to the full podcast episode!